Skip to content

Definium Therapeutics

US · DFTX #2132 by market cap Listed 1970
28.34 -1.14 -3.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/9/19
  • Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72
    Market Newswire · 2026/11/12
  • Company notice
    Legal Opinion on the First Extraordinary Shareholders' Meeting of Eastern Communications Co., Ltd. in 2024 by Zhejiang Tian Ce Law Firm.
    SZSI · 2024/8/2
  • Rating change
    RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/10/19
  • Rating change
    Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $67
    Market Newswire · 2026/9/16
  • Rating change
    A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $70 to $91
    Market Newswire · 2026/11/10
  • Rating change
    BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $91
    Market Newswire · 2026/10/7
  • Company notice
    Mind Medicine: Mind Medicine (MindMed) Inc. - Name/Symbol/CUSIP Change Option Symbol: MNMD New Symbol: DFTX
    OCC · 2026/1/15
  • Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/11/14
  • JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/11/12
  • Company notice
    Oriental Communications: Eastern Communications Co., Ltd. Fund Raising Management System (August 2025)
    SZSI · 2025/8/29
  • Company notice
    Announcement of the resolution of the first extraordinary general meeting of shareholders of Eastern Communications Co., Ltd. in 2024.
    SZSI · 2024/8/2
  • Rating change
    J.P. Morgan Initiates Definium Therapeutics(DFTX.US) With Buy Rating, Announces Target Price $84
    Market Newswire · 2026/10/9
  • Rating change
    LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/9/9
  • A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $78
    Market Newswire · 2026/11/11
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
    TipRanks · 2026/9/19
  • H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/11/9
  • Rating change
    A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91
    Market Newswire · 2026/9/15
  • Rating change
    Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
    TipRanks · 2026/10/7
  • Company notice
    Announcement from Eastern Communications Co., Ltd. Regarding the Resignation of Senior Management Personnel
    SZSI · 2024/8/27
  • Rating change
    BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/8/18
  • Rating change
    CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/9/2
  • Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/9/16
  • Rating change
    Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/8/31
  • Rating change
    JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/9/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Definium Therapeutics discussion 0 comments

Add a comment